Ukungcola kwe-Oseltamivir
| CHA. | Isakhiwo | I-CAS | Ubumsulwa |
| I-ASTW-1 | 204254-96-6 | ≧95% | |
| ASTW-2 | ≧95% | ||
| ASTW-3 | 347378-74-9 | ≧95% | |
| ASTW-4 | 1266663-89-1 | ≧95% | |
| I-ASTW-5 | 1533519-97-9 | ≧95% | |
| I-ASTW-6 | ≧95% | ||
| ASTW-7 | ≧95% | ||
| ASTW-8 (I-Oseltamivir EP Ukungcola A) | ≧95% | ||
| ASTW-9 (I-Oseltamivir EP Ukungcola B) | ≧95% | ||
| I-ASTW-10 (I-Oseltamivir EP Ukungcola C) | ≧95% | ||
| I-ASTW-11 (I-Oseltamivir EP Ukungcola D) | 1346604-18-9 | ≧95% | |
| I-ASTW-12 (I-Oseltamivir EP Ukungcola E) | 208720-78-9 | ≧95% | |
| I-ASTW-13 (Oseltamivir EP Ukungcola F) | 1052063-37-2 | ≧95% | |
| I-ASTW-14 (I-Oseltamivir EP Ukungcola G) | ≧95% | ||
| I-ASTW-15 (I-Oseltamivir异构体1) | ≧95% | ||
| I-ASTW-16 (I-Oseltamivir异构体2) | ≧95% | ||
| I-ASTW-17 (I-Oseltamivir异构体3) | ≧95% | ||
| I-ASTW-18 (I-Oseltamivir异构体4) | ≧95% | ||
| I-ASTW-19 (I-Oseltamivir异构体5) | ≧95% | ||
| I-ASTW-20 (I-Oseltamivir异构体6) | ≧95% | ||
| I-ASTW-21 (I-Oseltamivir异构体7) | ≧95% | ||
| I-ASTW-22 (OseltamivirImpurityK)
| ≧95% | ||
| I-ASTW-23 (OseltamivirImpurityI)
| ≧95% | ||
| I-ASTW-24
| ≧95% | ||
| I-ASTW-25
| ≧95% | ||
| I-ASTW-26
| ≧95% | ||
| I-ASTW-27
| ≧95% |
Ulwazi Lwenkampani
√ Isipiliyoni esigcwele se-Management layer kubalandeli befektri nabanekhono; √ Ikhwalithi ihlale iwukucatshangelwa kwethu okuphezulu, uhlelo oluqinile lwe-QC; √ Ithimba leminyaka engu-11 elinesipiliyoni sokuthumela ngaphandle; √ Ilebhu ye-R&D ezimele; √ Izinkundla zokucobelelana ngolwazi ezimbili ze-GMP zesikhathi eside ezisayiniwe; √ Izinsiza ezicebile zamafekthri amaningi angasebenzi wephrojekthi eyenziwe ngokwezifiso; √ Ithimba elisebenzayo elisebenza kahle elinendlela engaguquki.
